Status:
UNKNOWN
Tranexamic Acid and Spontaneous Chronic Urticaria
Lead Sponsor:
University Hospital, Grenoble
Conditions:
Chronic Spontaneous Urticaria
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Spontaneous chronic urticaria (UCS) is a disease that affects 1% of the general population with a potentially severe impact on quality of life. Most patients respond favorably to long-term antihistami...
Detailed Description
Multicentric controlled randomized crossover study, double-blind To evaluate the efficacy and safety of levocetirizine 10mg / day + tranexamic acid (AT) 2g / day versus levocetirizine 20mg / day alone...
Eligibility Criteria
Inclusion
- Patients with spontaneous chronic urticaria, according to the criteria of the European Academy of Allergology and Clinical Immunology (EAACI) in agreement with the European Dermatology Forum (EDF), and the World Allergy Organization (WAO), corresponding to an association of the following symptoms : urticarial eruptions and / or recurrent angioedema for at least 6 weeks
Exclusion
- Urticaria associated with a specific systemic disease including cutaneous and systemic mastocytosis, urticarial vasculitis, autoinflammatory diseases associated with cryopyrin
- Bradykinin angioedema and isolated angioedema whose origin is not clearly attributable to spontaneous chronic urticaria.
- Presence of a contraindication to tranexamic acid and to levocetirizine
Key Trial Info
Start Date :
December 10 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2022
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT03789422
Start Date
December 10 2019
End Date
September 1 2022
Last Update
April 28 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Grenoble-Alpes
Grenoble, France, 38043